Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

They work by mimicking the action of a hormone called glucagon-like peptide 1 (hence GLP-1), stimulating the body to produce more insulin and decreasing blood sugar spikes by slowing digestion.

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

Global Partners LP (NYSE:GLP) Q1 2024 Earnings Call Transcript May 8, 2024 Global Partners LP misses on earnings expectations. Reported EPS is $-0.37258 EPS, expectations were $0.1. GLP isn’t ...